Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963415 · ClinicalTrials.gov registry record · NA
Concurrent Aerobic Exercise and Virtual Reality Cognitive Training
A NA study of Preclinical Alzheimer's Disease, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT02963415: Completed NA study of Preclinical Alzheimer's Disease, sponsored by University of Minnesota.
NCT02963415 is a NA study of Preclinical Alzheimer's Disease that has completed, run by University of Minnesota. The registered enrollment target is 39 participants, below the 966-participant average among 3 other Preclinical Alzheimer's Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02963415, a NA study of Preclinical Alzheimer's Disease, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will implement and test a unique Virtual Reality Cognitive Training (VRCT) combined with concurrent cycling on a recumbent stationary cycle, also known as exergame that seamlessly integrates specific cognitive tasks into a virtual environment and is synchronized with cycling to promote cognition.
Primary Outcome
development of the exergame prototype by 3 months
Conditions Studied
Interventions
- BEHAVIORAL Exergame
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2022-03-31 |
| Phase | NA |
What the finished NCT02963415 record still lists
NCT02963415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 966-participant average among 3 other Preclinical Alzheimer's Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Preclinical Alzheimer's Disease appearing as the primary indexed condition, and to 1 intervention - of which Exergame is the first listed.
NCT02963415 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02963415 about?
NCT02963415 is a clinical study titled "Concurrent Aerobic Exercise and Virtual Reality Cognitive Training". The study will implement and test a unique Virtual Reality Cognitive Training (VRCT) combined with concurrent cycling on a recumbent stationary cycle, also known as exergame that seamlessly integrates specific cognitive tasks into a virtual environment and is synchronized with cycling to promote cog...
What is the current status of trial NCT02963415?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2019-03-01. Estimated completion is 2022-03-31.
What conditions does trial NCT02963415 study?
This clinical trial studies the following conditions: Preclinical Alzheimer's Disease.
What interventions are being tested in trial NCT02963415?
The interventions under investigation include: Exergame (BEHAVIORAL).
Who is sponsoring clinical trial NCT02963415?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02963415 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preclinical Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Alzheimer's Plasma Extension
ACTIVE NOT RECRUITING
-
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI